Skip to main content
. 2010 Oct 20;85(1):21–31. doi: 10.1128/JVI.01814-10

FIG. 4.

FIG. 4.

Comet and CMC plaque assays. BSC-40 cells were infected with VarV strain BSH (a) or with MPX (b). Cells were left untreated or treated with either PD-166326, dasatinib (BMS-354825), imatinib mesylate (STI-571), or nilotinib mesylate (AMN-107) at 10 μM, 1 μM, or 100 nM. Drugs were added 1 h after infection. Cells were incubated for 4 days, fixed, and stained with VarV PAb to recognize infected cells. For carboxymethyl cellulose plaque assays, BSC-40 cells were infected with VarV strain BSH (c) or with MPX (d) and overlaid with CMC. PD-166326, dasatinib (BMS-354825), imatinib mesylate (STI-571), or nilotinib melsylate (AMN-107) was added to a final concentration of 5 μM, 0.5 μM, or 50 nM 1 h after infection. Cells were incubated for 4 days, fixed, and stained with a VarV PAb to recognize infected cells.